button bars forest bayes pooled summary circles
 
deaths (OS)

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 0.76 [0.41; 1.40], 1 RCT, I2=0%
inconclusive result

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons